Baader Helvea downgraded Newron Pharma to Add from Buy with a price target of CHF 7.20, up from CHF 2.60. The analyst updated the model to account for evenamide’s recent success in the open-label trial in treatment-resistant schizophrenia. It cites valuation for the downgrade.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly